3 Stocks Near 52-Week Lows Worth Buying

Just as we examine companies each week that may be rising past their fair value, we can also find companies potentially trading at bargain prices. While many investors would rather have nothing to do with companies tipping the scales at 52-week lows, I think it makes a lot of sense to determine whether the market has overreacted to the downside, just as we often do when the market reacts to the upside.

Here's a look at three fallen angels trading near their 52-week lows that could be worth buying.

The sun may shine once again
There's little doubt that the solar sector has been filled with a myriad of ups and downs over the previous couple of years. Many domestic names have rallied dramatically off their lows as the prospect of President Obama's energy independence initiatives have boosted project demand; and others like GT Advanced Technologies (NASDAQOTH: GTATQ  ) , which provides equipment to solar companies in the manufacture of solar wafers, have done nothing but head lower.

At the heart of GTAT's problems, as Foolish solar expert Travis Hoium pointed out on Friday, is the simple fact that there's still too much supply out there. Specifically, Chinese producers like LDK Solar (NASDAQOTH: LDKYQ  ) purchased equipment hand over fist years ago when it appeared as if solar demand would be insatiable, and government subsidies endless. Unfortunately, costs for Chinese manufacturers like LDK have been rising, demand has dropped, and plenty of capacity sits idle, meaning even if business does tick higher, equipment orders from China may be minimal. LDK, for instance, boasts a ridiculous $3 billion in net debt. 

The good news here is that, over the long run, supply is going to normalize, and solar companies with little capital will bow out and create opportunities for U.S. domestic solar production. GTAT still boasts $121.1 million in net cash and management expressed confidence that the second half of the year would see a rebound in its core business. Even if GTAT hits the low end of its projected 2013 guidance, it's only valued at 11 times this year's earnings, or,  stripping out its cash value, just 6.5 times this year's earnings.

Put some green in your portfolio
Many of you are quite familiar with my distrust of "green" energy companies, but for one day, at least, I'm putting aside my differences and welcoming Ameresco (NYSE: AMRC  ) into the mix. Ameresco provides energy infrastructure improvements, solutions, and consulting to the energy industry, as well as enterprises and the government.

As you might imagine, in very similar fashion to the discussion regarding GTAT, a lull in solar demand has put a lid on Ameresco's near-term profitability. However, other factors, including the negative effects of Superstorm Sandy and the delay of its fourth-quarter earnings report in order to examine how to quantify one of its hedges (the press release actually gave me a headache), have contributed to pressuring Ameresco's share price.  

Still, President Obama's tax credits offered for energy-efficient upgrades are unlikely to go away even with the sequester now ready to go into effect. As federal spending drops and enterprises look for new pathways to grow their bottom line, one avenue they're likely to turn to is energy efficiency. Although it means more out-of-pocket costs now to upgrade, many of the upgrades are tax-deductible and they result in long-term cost savings. A fourth-quarter update provided in mid-February notes that Ameresco still has a $1.5 billion backlog and, based on current Wall Street estimates, is valued at a reasonable 13 times forward earnings.

How Siri can help you
Word to the wise: If you ride Apple's coattails and Apple gets tripped up, you're going for a ride.

Nuance Communications (NASDAQ: NUAN  ) , maker of the speech recognition software found in Apple's newer iPhone devices and in the health care market, sank like a concrete block last month after it slightly lowered its full-year sales and EPS guidance to a range of $1.76 to $1.87 on $2.15 billion to $2.2 billion in sales from its previous forecast of $1.84 to $1.94 and $2.17 billion to $2.22 billion in sales. Investors have lopped off $1.9 billion in market value since this announcement. To say I think this is a major overreaction would be the understatement of the week!

Part of the problem relates to health care upgrades, which are moving away from Nuance's health care technology to Dragon Medical speech-to-text software. While this was unavoidable, it's also a transition that's happening incredibly slow, so it isn't as if Nuance's revenue stream is going to dry up overnight. Also, greatly exaggerated stories of Apple's demise and the company cutting back on iPhone component orders has unfairly affected Nuance's share price. Siri, essentially the voice of Apple, is going to remain a mainstay in its iPhone and iPad and, last I checked, total combined unit sale estimates were only rising.

Nuance is projected to grow by an average of 19% over the next two years, yet it's only valued at nine times forward earnings. Can you say "Hello, Mr. Opportunity"?

Foolish roundup
This week's theme is all about inference. It may not be blatantly obvious that GTAT and Ameresco are going to benefit from Obama's energy initiatives, or that Nuance is going to come out smelling like a rose even with Apple's woes, but the tools for success are clearly visible in all three cases.

I'm so confident that these three names will bounce off their lows that I'm going to make a CAPScall of outperform on each one.

Is this a major value or a value trap?
Speech recognition is yet another nascent technology set to explode with the rise of tablets and smartphones, and no company is better poised to benefit from this coming boom than Nuance Communications. However, this growth story doesn't come without risks, too. The Motley Fool recently published a premium research report to break down what investors interested in Nuance absolutely have to understand before investing, so click here now to grab your copy today.


Read/Post Comments (1) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 20, 2013, at 2:58 PM, banjr wrote:

    "Part of the problem relates to health care upgrades, which are moving away from Nuance's health care technology to Dragon Medical speech-to-text software."

    What are you talking about? Dragon is a Nuance product. Are you trying to say that the margins on Dragon are significantly lower than transcription services? I didn't think that was the case. Please explain.

    Thanks.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2293350, ~/Articles/ArticleHandler.aspx, 12/21/2014 12:17:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement